Back to top

messenger-rna: Archive

Zacks Equity Research

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

MRKNegative Net Change MRNANegative Net Change EXASNegative Net Change BNTXNegative Net Change